Hence, it is appealing to explore the clinicopathological characteristics and molecular associations of NSCLC expressing PD-1 or PD-L1, which might be candidates for anti-PD-1/PD-L1 immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.